Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Syndax Pharma (SNDX)
Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,159,523
  • Shares Outstanding, K 69,641
  • Annual Sales, $ 0 K
  • Annual Income, $ -149,340 K
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.26
Trade SNDX with:

Options Overview Details

View History
  • Implied Volatility 92.21% ( -5.06%)
  • Historical Volatility 46.98%
  • IV Percentile 79%
  • IV Rank 22.52%
  • IV High 230.38% on 09/29/23
  • IV Low 52.03% on 05/30/23
  • Put/Call Vol Ratio 0.13
  • Today's Volume 1,093
  • Volume Avg (30-Day) 1,323
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 22,395
  • Open Int (30-Day) 21,077

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.00
  • Number of Estimates 6
  • High Estimate -0.92
  • Low Estimate -1.15
  • Prior Year -0.62
  • Growth Rate Est. (year over year) -61.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.14 +36.53%
on 11/13/23
18.32 -2.07%
on 12/11/23
+4.39 (+32.40%)
since 11/10/23
3-Month
11.22 +59.96%
on 10/23/23
18.32 -2.07%
on 12/11/23
+0.58 (+3.34%)
since 09/11/23
52-Week
11.22 +59.96%
on 10/23/23
29.86 -39.92%
on 02/02/23
-2.70 (-13.08%)
since 12/09/22

Most Recent Stories

More News
Syndax: Q3 Earnings Snapshot

Syndax: Q3 Earnings Snapshot

SNDX : 17.94 (+7.75%)
3 Revolutionary Biotech Stocks Worth Investing In

The biotech industry's upward momentum is underpinned by the growth of personalized medicine, orphan drugs, innovative biotech tools, and robust government backing. Hence, revolutionary biotech stocks...

EQ : 0.6360 (-6.47%)
INCY : 57.04 (+4.28%)
PLX : 1.5800 (-3.07%)
REPL : 7.45 (+2.19%)
SNDX : 17.94 (+7.75%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 17.94 (+7.75%)
Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis

– Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an additional 14%...

SNDX : 17.94 (+7.75%)
Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 17.94 (+7.75%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 17.94 (+7.75%)
Syndax Announces Participation at the Citi 18th Annual BioPharma Conference

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 17.94 (+7.75%)
3 Best Biotech Stocks for Health and Wealth

With medical innovations and technological breakthroughs rapidly transforming the healthcare landscape, biotech stocks have garnered unprecedented attention in the investment community. Thus, fundamentally...

AMGN : 272.14 (+1.12%)
INCY : 57.04 (+4.28%)
REPL : 7.45 (+2.19%)
SNDX : 17.94 (+7.75%)
VRTX : 356.29 (+1.75%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 17.94 (+7.75%)
Syndax: Q2 Earnings Snapshot

Syndax: Q2 Earnings Snapshot

SNDX : 17.94 (+7.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 17.42
2nd Resistance Point 17.21
1st Resistance Point 16.93
Last Price 17.94
1st Support Level 16.44
2nd Support Level 16.23
3rd Support Level 15.95

See More

52-Week High 29.86
Fibonacci 61.8% 22.74
Fibonacci 50% 20.54
Fibonacci 38.2% 18.34
Last Price 17.94
52-Week Low 11.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar